迪瑞醫療(300396.SZ)擬變更經營範圍 涉非醫用防護用品的銷售及進出口等
格隆匯4月3日丨迪瑞醫療(300396.SZ)公佈,公司於2020年4月2日收到公司控股股東長春瑞發投資有限公司的《關於增加2020年第一次臨時股東大會臨時提案的函》,提請董事會將《關於修改<公司章程>的議案》作為臨時議案提交2020年第一次臨時股東大會審議。公司於2020年4月3日召開第四屆董事會第五次臨時會議,審議通過了《關於修改<公司章程>的議案》。
因公司業務發展需要,結合公司自身業務實際情況,擬變更經營範圍及《公司章程》相應條款作出修訂,具體修訂內容如下:
原公司章程條款:第十三條:經依法登記,公司的經營範圍為:從事醫療科技領域的技術開發、技術轉讓、技術諮詢及技術服務,生產III類6840臨牀檢驗分析儀器、III類6840體外診斷試劑、II類6840臨牀檢驗分析儀器、II類6840體外診斷試劑(醫療器械生產許可證到2020年6月22日)、I類6840臨牀檢驗分析儀器及I類6840體外診斷試劑;醫療器械的經營(按醫療器械許可證核定範圍經營);自產產品的原輔材料及半成品、科研所需原輔材料、機械設備、儀器儀表的銷售,軟件開發、銷售,生產經營產品的售後服務及租賃業務(依法須經批准的項目,經相關部門批准後方可開展經營活動)。
修訂後的公司章程條款:第十三條:經依法登記,公司的經營範圍為:從事醫療科技領域的技術開發、技術轉讓、技術諮詢及技術服務,生產2002分類目錄(Ⅱ類:6840-1-血液分析系統;6840-2-生化分析系統;6840-3-免疫分析系統;6840-5-尿液分析系統;6840-體外診斷試劑。Ⅲ類:6840-體外診斷試劑);2017年分類目錄(Ⅱ類:6840-體外診斷試劑;22-01-血液學分析設備;22-02-生化分析設備;22-04-免疫分析設備;22-09-尿液及其他樣本分析設備,22-10-其他醫用分析設備。Ⅲ類6840-體外診斷試劑)(醫療器械生產許可證到2025年2月27日);I類6840臨牀檢驗分析儀器及I類6840體外診斷試劑;醫療器械的經營(按醫療器械許可證核定範圍經營);自產產品的原輔材料及半成品、科研所需原輔材料、機械設備、儀器儀表的銷售,軟件開發、銷售,生產經營產品的售後服務及租賃業務;非醫用防護用品的銷售及進出口(依法須經批准的項目,經相關部門批准後方可開展經營活動)。(具體以工商行政管理部門最終核准、登記為準。)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.